Go to Header
Go to Navigation
Go to Content
Go to Footer
Login
Help
中文（繁體）
Research Resources
CUHK UPDates
Theses
Experts List
User Guides
About Us
List of Researchers
> Associate Professor Herbert Ho Fung LOONG
Home
Research Outputs
Researcher Profiles
Department Profiles
Research Areas
Professor LOONG Herbert Ho Fung
Personal Information
Position and Department
Associate Professor
,
Department of Clinical Oncology
ORCiD
0000-0002-6607-1106
CUHK Research Outputs
2 of 5
EP03.01-011 Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong
(
2022
)
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
(
2022
)
Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches
(
2022
)
KontRASt-01: A Phase Ib/II Dose Escalation Study of JDQ443 in Patients with advanced KRAS G12C mutated solid Tumors
(
2022
)
LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC
(
2022
)
Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas
(
2022
)
Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
(
2022
)
Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
(
2022
)
Update on the Recommendations on Breast Cancer Screening by the Cancer Expert Working Group on Cancer Prevention and Screening
(
2022
)
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
(
2022
)
A phase 2 study of oral paclitaxel and encequidar (oPac plus E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup
(
2021
)
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion plus NSCLC and RET-mutant MTC: Phase 1 study results
(
2021
)
Commissioned Programme on the CUHK Phase 1 Clinical Trial Centre at the Prince of Wales Hospital
(
2021
)
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
(
2021
)
Economic Impact of Next-Generation Sequencing (NGS) vs. Single-gene Testing Strategies to Detect Genomic Alterations (GAs) in mNSCLC in Asia
(
2021
)
Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
(
2021
)
EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma
(
2021
)
Health-related quality of life of glioblastoma patients receiving post-operative concomitant chemoradiotherapy plus adjuvant chemotherapy: A longitudinal study
(
2021
)
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
(
2021
)
LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
(
2021
)
Local Ablative Radiotherapy on Oligo-Progression while Continued on EGFR-TKI in Advanced NSCLC Patients: A Longer Cohort
(
2021
)
Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non–small cell lung cancer patients: A longer cohort
(
2021
)
Management of Malignancies Developing in AYA
(
2021
)
Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
(
2021
)
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
(
2021
)
Phase III study of selpercatinib versus chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer
(
2021
)
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review
(
2021
)
Safety of selpercatinib for RET-altered advanced solid tumors: a post hoc analysis of LIBRETTO-001
(
2021
)
Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)
(
2021
)
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium
(
2021
)
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
(
2020
)
A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma.
(
2020
)
Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study
(
2020
)
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
(
2020
)
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
(
2020
)
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
(
2020
)
Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
(
2020
)
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
(
2020
)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
(
2020
)
Examining Patient Preferences for Integrative Chinese-Western Colorectal Cancer Care in Hong Kong
(
2020
)
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
(
2020
)
Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?
(
2020
)
Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases
(
2020
)
Preservation of fertility in premenopausal patients with breast cancer
(
2020
)
Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas
(
2020
)
Proceedings of the 3rd Chinese University of Hong Kong (CUHK) Sarcoma Masterclass, September 21, 2019
(
2020
)
Randomized study to determine the efficacy of Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese breast cancer patients (PTS)
(
2020
)
Selpercatinib (LOXO-292) in patients with RET-fusion plus non-small cell lung cancer
(
2020
)
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma
(
2020
)
Tropomyosin receptor kinase inhibitors in the management of sarcomas
(
2020
)
Most Relevant Area
Oncology
(
Internal medicine related
)
Share Link
Last updated on 2024-03-09 at 16:09
Share Link
Your name*
Your email*
Recipient's name*
Recipient's email*
Message
Auxilliary Information
No information will be stored or shared with any third party.
Cancel
Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ok to Continue
Cookie Policy
